|
Non-Small Cell Lung Carcinoma
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
To understand further the role of Met receptor overexpression in non-small-cell lung carcinoma, we forced-expressed the full-length met cDNA in the NCI-H1264 (H1264) lung carcinoma cell line with low constitutive expression of this receptor.
|
11795945 |
2002 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most interesting findings were two MET mutations that have recently been implemented in NSCLC.
|
16171945 |
2006 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine MET copy number related to EGFR copy number and K-Ras mutations in a targeted TKI naive NSCLC cohort.
|
18379349 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, the results support a critical role of Met gene dose in NSCLC, suggesting that Met may be a specific molecular therapeutic target in selected NSCLC patients with increased Met copy number.
|
19037978 |
2008 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MET copy number was examined in 28 NSCLC and 4 human bronchial epithelial cell lines (HBEC) and 100 primary tumors using quantitative real-time PCR.
|
19117057 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We analyzed MET gene copy number using FISH in two related NSCLC cell lines, one sensitive (HCC827) and one resistant (HCC827 GR6) to gefitinib therapy and in two different NSCLC patient populations: 24 never smokers or EGFR FISH-positive patients treated with gefitinib (ONCOBELL cohort) and 182 surgically resected NSCLC not exposed to anti-EGFR agents.
|
18836087 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is dysregulated via overexpression, constitutive activation, gene amplification, ligand-dependent activation, mutation or epigenetic mechanisms.
|
18672314 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PXN mutations and PXN amplifications were recently identified in nonsmall-cell lung cancer (NSCLC) and amplifications were associated with MET increased copy number.
|
19353596 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MET increased gene copy number is an independent negative prognostic factor in surgically resected NSCLC.
|
19255323 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the addition of S-1 to EGFR-TKIs is a promising strategy to overcome EGFR-TKI resistance in NSCLC with MET amplification.
|
19188161 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
|
19381876 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The growing preclinical data in EGFR-mutated NSCLCs with acquired resistance to gefitinib or erlotinib has spawned the initiation or conception of clinical trials testing novel EGFR inhibitors that in vitro inhibit T790M (neratinib, XL647, BIBW 2992, and PF-00299804), MET, or IGF-1R inhibitors in combination with EGFR TKIs, and heat shock protein 90 inhibitors.
|
19632948 |
2009 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings support an intimate relationship between the EGFR and MET signaling pathways in NSCLC, and they suggest that combination treatment with MET and EGFR kinase inhibitors may be beneficial in MET-amplified NSCLC by reducing selection for drug resistant clones.
|
20124471 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We investigate the clinicopathologic features of MET gene copy in nonsmall cell lung cancer (NSCLC).
|
20107422 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We determined the genetic variations of c-CBL, relationship to receptor tyrosine kinases (EGFR and MET), and functionality in NSCLC.
|
20126411 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our analysis of 202 NSCLC patient specimens was consistent with these observations: levels of MET were significantly higher in NSCLC with EGFR mutations than in NSCLC with wild-type EGFR.
|
20154724 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Most non-small cell lung cancer (NSCLC) tumors with activating mutations of the epidermal growth factor receptor (EGFR) are initially responsive to first-generation, reversible EGFR tyrosine kinase inhibitors (TKI) such as gefitinib, but they subsequently develop resistance to these drugs through either acquisition of an additional T790M mutation of EGFR or amplification of the proto-oncogene MET.
|
20530710 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.
|
20129249 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here we report that Met protein expression and phosphorylation were associated with primary resistance to EGFR TKI therapy in NSCLC patients harboring EGFR mutations, implicating Met as a de novo mechanism of resistance.
|
20489150 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results provide a rationale for clinical targeting of Src in gefitinib-resistant NSCLC with MET amplification.
|
19804422 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Results from ongoing and future trials will clarify the role of MET TKIs for the treatment of NSCLC and will provide insights into the most appropriate timing for their use.
|
20146583 |
2010 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
But it remains uncertain whether MET amplification could be related to primary TKI resistance in NSCLC because of limited data.
|
22052229 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
MET is overexpressed in 61% of NSCLC cases.
|
21815704 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The involvement of the MET oncogene in de novo and acquired resistance of non-small cell lung cancers (NSCLCs) to tyrosine kinase inhibitors (TKIs) has previously been reported, but the precise mechanism by which MET overexpression contributes to TKI-resistant NSCLC remains unclear.
|
22157681 |
2011 |